TW200520759A - Pharmaceutical composition and combination - Google Patents

Pharmaceutical composition and combination Download PDF

Info

Publication number
TW200520759A
TW200520759A TW093129854A TW93129854A TW200520759A TW 200520759 A TW200520759 A TW 200520759A TW 093129854 A TW093129854 A TW 093129854A TW 93129854 A TW93129854 A TW 93129854A TW 200520759 A TW200520759 A TW 200520759A
Authority
TW
Taiwan
Prior art keywords
coating
composition
rapamycin
small
sodium
Prior art date
Application number
TW093129854A
Other languages
English (en)
Chinese (zh)
Inventor
Dieter Becker
Carsten Burger
Gilles Feutren
Patrice Guitard
Andrea Kramer
Nicoletta Loggia
Christian-Peter Luftensteiner
Jorg Ogorka
Harald Ottinger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0323202A external-priority patent/GB0323202D0/en
Priority claimed from GB0323598A external-priority patent/GB0323598D0/en
Priority claimed from GB0329852A external-priority patent/GB0329852D0/en
Priority claimed from GB0405902A external-priority patent/GB0405902D0/en
Priority claimed from GB0410714A external-priority patent/GB0410714D0/en
Priority claimed from GB0419356A external-priority patent/GB0419356D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200520759A publication Critical patent/TW200520759A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW093129854A 2003-10-03 2004-10-01 Pharmaceutical composition and combination TW200520759A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0323202A GB0323202D0 (en) 2003-10-03 2003-10-03 Organic compounds
GB0323598A GB0323598D0 (en) 2003-10-08 2003-10-08 Organic compounds
GB0329852A GB0329852D0 (en) 2003-12-23 2003-12-23 Organic compounds
GB0405902A GB0405902D0 (en) 2004-03-16 2004-03-16 Organic compounds
GB0410714A GB0410714D0 (en) 2004-05-13 2004-05-13 Organic compounds
GB0419356A GB0419356D0 (en) 2004-08-31 2004-08-31 Organic compounds

Publications (1)

Publication Number Publication Date
TW200520759A true TW200520759A (en) 2005-07-01

Family

ID=34437795

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093129854A TW200520759A (en) 2003-10-03 2004-10-01 Pharmaceutical composition and combination

Country Status (11)

Country Link
US (1) US20070036857A1 (cg-RX-API-DMAC7.html)
EP (1) EP1670437A1 (cg-RX-API-DMAC7.html)
JP (1) JP2007507458A (cg-RX-API-DMAC7.html)
AR (1) AR045957A1 (cg-RX-API-DMAC7.html)
AU (1) AU2004280078B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414864A (cg-RX-API-DMAC7.html)
CA (1) CA2538099A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003646A (cg-RX-API-DMAC7.html)
PE (1) PE20050755A1 (cg-RX-API-DMAC7.html)
TW (1) TW200520759A (cg-RX-API-DMAC7.html)
WO (1) WO2005034916A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003064383A2 (en) 2002-02-01 2003-08-07 Ariad Gene Therapeutics, Inc. Phosphorus-containing compounds & uses thereof
GB0419355D0 (en) * 2004-08-31 2004-09-29 Novartis Ag Organic compounds
US20060235009A1 (en) 2005-02-08 2006-10-19 Richard Glickman Treatment of vascular, autoimmune and inflammatory diseases using low dosages of IMPDH inhibitors
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
CN101378749A (zh) * 2006-02-13 2009-03-04 诺瓦提斯公司 高剂量的麦考酚酸(mpa)
US20080161335A1 (en) * 2006-11-14 2008-07-03 Vladyka Ronald S Oral formulations
BRPI0816231A2 (pt) * 2007-08-13 2015-06-16 Panacea Biotec Ltd Composições de liberação prolongada compreendendo micofenolato de sódio e seus processos
EP2262483A2 (en) * 2008-03-05 2010-12-22 Panacea Biotec Limited Modified release pharmaceutical compositions comprising mycophenolate and processes thereof
EP2446027A1 (en) * 2009-06-25 2012-05-02 Danisco A/S Protein
EP2488173A1 (en) * 2009-10-13 2012-08-22 Teva Pharmaceutical Industries Ltd. Delayed release compositions
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2763663B1 (en) * 2011-10-06 2017-12-27 Novartis AG Pharmaceutical compositions comprising 40-o-(2-hydroxy)ethyl-rapamycin
JP2015533174A (ja) * 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
WO2014167442A1 (en) * 2013-03-26 2014-10-16 Wockhardt Limited Pharmaceutical compositions comprising mycophenolic acid or salts thereof
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
MA40982A (fr) * 2014-11-19 2017-09-26 Biogen Ma Inc Formulation de bille pharmaceutique comprenant du fumarate de diméthyle
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
WO2018096402A1 (en) 2016-11-23 2018-05-31 Novartis Ag Methods of enhancing immune response with everolimus, dactolisib or both
MX2019010829A (es) * 2017-03-13 2020-02-05 Okava Pharmaceuticals Inc Metodos y composiciones para suministrar agentes activos de acido micofenolico a mamiferos no humanos.
WO2019157516A1 (en) 2018-02-12 2019-08-15 resTORbio, Inc. Combination therapies
US11446055B1 (en) 2018-10-18 2022-09-20 Lumoptik, Inc. Light assisted needle placement system and method
US20250282721A9 (en) * 2021-12-23 2025-09-11 Gencaps Sàrl Drug delivery system comprising monomethyl fumarate
US20250327799A1 (en) * 2022-05-16 2025-10-23 Mayo Foundation For Medical Education And Research Assessing and treating caveolinopathy diseases

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
PT721335E (pt) * 1993-10-01 2005-11-30 Roche Palo Alto Llc Suspensoes orais em altas doses de micofenolato de mofetil
ID18663A (id) * 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
EP1097705A2 (en) * 1996-10-14 2001-05-09 F. Hoffmann-La Roche Ag Process for the manufacture of a pulverous preparation
US6890546B2 (en) * 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
MXPA04006731A (es) * 2002-01-10 2004-10-04 Novartis Ag Sistema de administracion de farmacos que comprenden rapamicina y derivados de la misma para la prevencion y tratamiento de enfermedades vasculares.
ES2428354T3 (es) * 2002-09-18 2013-11-07 Trustees Of The University Of Pennsylvania Rapamicina para usar en la inhibición o prevención de la neovascularización coroidea
CA2500908A1 (en) * 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
GB0301259D0 (en) * 2003-01-20 2003-02-19 Novartis Ag Organic compounds
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2005034916A1 (en) 2005-04-21
AU2004280078A1 (en) 2005-04-21
JP2007507458A (ja) 2007-03-29
CA2538099A1 (en) 2005-04-21
US20070036857A1 (en) 2007-02-15
MXPA06003646A (es) 2006-06-05
EP1670437A1 (en) 2006-06-21
BRPI0414864A (pt) 2006-11-28
AR045957A1 (es) 2005-11-16
AU2004280078B2 (en) 2008-08-07
PE20050755A1 (es) 2005-11-28

Similar Documents

Publication Publication Date Title
TW200520759A (en) Pharmaceutical composition and combination
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
JP5634882B2 (ja) 弱塩基性薬物と有機酸とを含む薬物送達システム
JP6368242B2 (ja) ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
ES2292819T3 (es) Composiciones farmaceuticas que comprenden acido micofenolico o sal de micofenolato.
US20080206322A1 (en) Pharmaceutical Multiparticulate Composit Ion Comprising Mycophenolic Acid or Myco Phenolate Sodium and Combination Compositions with Rapamycin
KR20080007252A (ko) 양성 전립선 과다형성증용 치료 조합물
EP1154762B1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US20150140089A1 (en) Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
US20050226927A1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
CA2578375A1 (en) Vaccine immunotherapy for immune suppressed patients
US20050220873A1 (en) Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
WO2005097079A2 (en) Controlled release dosage for gaba receptor agonist
US20050220874A1 (en) Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20050220863A1 (en) Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
US20050220864A1 (en) Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
MXPA06004017A (es) Formas de dosis una vez al dia de trospio
HK1196567A (en) Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin
HK1196567B (en) Pharmaceutical compositions comprising 40 - o - ( 2 - hydroxy) ethyl - rapamycin